- Home
- WEC vs ALNY Comparison
WEC vs ALNY Comparison
Compare WEC & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEC | ALNY |
|---|---|---|
| Founded | 1896 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2B | 34.2B |
| IPO Year | 1995 | 2004 |
Fundamental Metrics
Financial Performance| Metric | WEC | ALNY |
|---|---|---|
| Price | $101.73 | $231.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 29 |
| Target Price | $121.62 | ★ $371.12 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | ★ 4.81 | 2.71 |
| Revenue | ★ $9,800,100,000.00 | $1,037,418,000.00 |
| Revenue This Year | $4.79 | $47.63 |
| Revenue Next Year | $5.26 | $26.74 |
| P/E Ratio | ★ $21.41 | $93.37 |
| Revenue Growth | 13.96 | ★ 22.88 |
| 52 Week Low | $100.14 | $197.81 |
| 52 Week High | $119.91 | $495.55 |
Technical Indicators
Market Signals| Indicator | WEC | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 31.34 | 51.00 |
| Support Level | N/A | $236.00 |
| Resistance Level | $107.42 | $272.08 |
| Average True Range (ATR) | 1.48 | 7.86 |
| MACD | -0.13 | 0.25 |
| Stochastic Oscillator | 3.82 | 64.74 |
Price Performance
Historical ComparisonAbout WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 30% gas distribution, 10% electric transmission, 9% unregulated renewable energy, and 2% LNG distribution and generation.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.